Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window.

ABSTRACT:

Introduction

We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years after plasma collection (range 1.01-10.47).

Methods

We included 215 participants from the PREVENT-AD cohort with plasma Aβ_42/40 and p-tau217, 159 with cerebrospinal fluid (CSF) Aβ_42/40 and p-tau217, and 155 with ¹⁸F-NAV4694 and ¹⁸F-flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.

Results

Cox proportional hazard models indicated a greater progression rate in A+T+_plasma and A-T+_plasma compared to

SUBMITTER: Yakoub Y 

PROVIDER: S-EPMC11863240 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature